Sort by
Refine Your Search
-
Listed
-
Category
-
Employer
- University of Cambridge
- Cranfield University
- University of Birmingham
- University of East Anglia
- University of East Anglia;
- King's College London
- University of Birmingham;
- University of Nottingham
- ; University of Surrey
- The University of Manchester
- ;
- AALTO UNIVERSITY
- The University of Manchester;
- University of Cambridge;
- University of Leeds
- University of Newcastle
- ; King's College London
- ; Manchester Metropolitan University
- ; University of Plymouth
- ; University of Southampton
- Abertay University
- Durham University;
- King's College London;
- Loughborough University
- Loughborough University;
- Newcastle University;
- Swansea University
- The University of Edinburgh
- University of Bristol
- University of Derby
- University of Exeter
- University of Exeter;
- University of Manchester
- University of Nottingham;
- University of Plymouth
- University of Salford;
- University of Sheffield
- University of Sheffield;
- University of Surrey;
- University of Sussex;
- University of Warwick
- 31 more »
- « less
-
Field
-
Oral targeted drug delivery in the gastrointestinal (GI) tract is highly sought for treating localized conditions like inflammatory bowel disease (IBD). Traditional approaches rely on passive
-
as fertile targets for drug discovery and development (approx. 30% of all drugs target this family). Extensive research has characterized GPCR signalling at the cell surface, however more recent
-
Spinal cord injury (SCI) leads to devastating and often permanent loss of movement and sensation, yet there are currently no effective therapies to restore function. This PhD project will investigate new strategies to protect and regenerate nerve cells after SCI by combining molecular biology,...
-
Supervisors: Dr Tim Halim and Dr Gregory Hamm Course start: 1st October 2026 Overview The project will be supervised by Dr Tim Halim, Dr Albert Koulman (Institute of Metabolic Science) and Dr Gregory Hamm (AstraZeneca). Project details The tumour immunity cycle involves cyclical trafficking of...
-
resistance and a profoundly immunosuppressive tumour microenvironment (TME). There is a critical need for novel therapeutic strategies that target both tumour-intrinsic mechanisms and immune evasion. Our
-
Supervisors: Professor Sir Steve Jackson and Dr Mark O'Connor (AZ Partner) Course start date: 1st October 2026 Project details Targeted Alpha Therapy (TAT) selectively delivers high Linear Energy
-
-consuming and often fail to express target proteins at sufficient levels. In this project, you will investigate whether mammalian cell lines can be genetically altered to enhance expression of challenging
-
approach utilises the inherent need of the tumour for extracellular arginine and to use this to deliver a toxic moiety to the tumour; in other words, we will use the arginine structural motif as a targeting
-
the gut-brain and gut-muscle axes, as potentially key modulators of cognitive function, and physical health in middle-aged-to-older adults. The central theme will be to investigate how targeted
-
Paediatric services, including KCH), and age- and gender-matched healthy controls. Parts 2 and 3 are under development. Part 2 will involve a targeted neuroimaging (EEG and/or fMRI) intervention study with a